| VIS ID | Virus | Ensembl ID | Gene Type | Target Gene | Oncogene | Tumor Suppressor Gene | NCBI ID | Uniprot ID |
|---|---|---|---|---|---|---|---|---|
| TVIS42001696 | EBV | ENSG00000077782.23 | protein_coding | FGFR1 | Yes | No | 2260 | A0A0S2Z3Q6 P11362 |
| TVIS10017407 | HBV | ENSG00000077782.23 | protein_coding | FGFR1 | Yes | No | 2260 | A0A0S2Z3Q6 P11362 |
| TVIS30009529 | HIV | ENSG00000077782.23 | protein_coding | FGFR1 | Yes | No | 2260 | A0A0S2Z3Q6 P11362 |
| TVIS30009530 | HIV | ENSG00000077782.23 | protein_coding | FGFR1 | Yes | No | 2260 | A0A0S2Z3Q6 P11362 |
| TVIS30068820 | HIV | ENSG00000077782.23 | protein_coding | FGFR1 | Yes | No | 2260 | A0A0S2Z3Q6 P11362 |
| TVIS30068821 | HIV | ENSG00000077782.23 | protein_coding | FGFR1 | Yes | No | 2260 | A0A0S2Z3Q6 P11362 |
| TVIS30068822 | HIV | ENSG00000077782.23 | protein_coding | FGFR1 | Yes | No | 2260 | A0A0S2Z3Q6 P11362 |
| TVIS30068823 | HIV | ENSG00000077782.23 | protein_coding | FGFR1 | Yes | No | 2260 | A0A0S2Z3Q6 P11362 |
| TVIS30068824 | HIV | ENSG00000077782.23 | protein_coding | FGFR1 | Yes | No | 2260 | A0A0S2Z3Q6 P11362 |
| TVIS20031100 | HPV | ENSG00000077782.23 | protein_coding | FGFR1 | Yes | No | 2260 | A0A0S2Z3Q6 P11362 |
Target Gene Table
▼
TCGA Plot Options
▼
Drug Information
▼
| Gene | FGFR1 |
|---|---|
| DrugBank ID | DB12147 |
| Drug Name | Erdafitinib |
| Target ID | BE0002131 |
| UniProt ID | P11362 |
| Regulation Type | inhibitor |
| PubMed IDs | 28965185; 26324363 |
| Citations | Nishina T, Takahashi S, Iwasawa R, Noguchi H, Aoki M, Doi T: Safety, pharmacokinetic, and pharmacodynamics of erdafitinib, a pan-fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitor, in patients with advanced or refractory solid tumors. Invest New Drugs. 2018 Jun;36(3):424-434. doi: 10.1007/s10637-017-0514-4. Epub 2017 Sep 30.@@Tabernero J, Bahleda R, Dienstmann R, Infante JR, Mita A, Italiano A, Calvo E, Moreno V, Adamo B, Gazzah A, Zhong B, Platero SJ, Smit JW, Stuyckens K, Chatterjee-Kishore M, Rodon J, Peddareddigari V, Luo FR, Soria JC: Phase I Dose-Escalation Study of JNJ-42756493, an Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients With Advanced Solid Tumors. J Clin Oncol. 2015 Oct 20;33(30):3401-8. doi: 10.1200/JCO.2014.60.7341. Epub 2015 Aug 31. |
| Groups | Approved; Investigational |
| Direct Classification | Alkyldiarylamines |
| SMILES | COC1=CC(=CC(OC)=C1)N(CCNC(C)C)C1=CC=C2N=CC(=NC2=C1)C1=CN(C)N=C1 |
| Pathways | |
| PharmGKB | |
| ChEMBL | CHEMBL3545376 |
